Summary of Orchid Island Capital, Inc. News Core Viewpoint Orchid Island Capital, Inc. has declared a monthly cash dividend of $0.12 per share for August 2025, with plans for regular monthly distributions to its common stockholders. The company is focused on maintaining its status as a real estate investment trust (REIT) by distributing at least 90% of its taxable income. Group 1: Dividend Announcement - The Board of Directors declared a monthly cash dividend of $0.12 per share for August 2025, payable on September 29, 2025, to stockholders of record as of August 29, 2025, with an ex-dividend date of August 29, 2025 [1] - The next common stock dividend announcement is expected on September 8, 2025 [7] Group 2: REIT Compliance and Distribution Strategy - To qualify as a REIT, the company must distribute annually at least 90% of its REIT taxable income, excluding net capital gains [2] - The company has not established a minimum distribution payment level and does not guarantee future distributions [2] Group 3: Shareholder Information - As of August 13, 2025, the company had 133,172,673 shares of common stock outstanding, an increase from 130,595,848 shares as of July 31, 2025 [3] Group 4: RMBS Portfolio Characteristics - Orchid Island Capital, Inc. invests in Agency RMBS, focusing on traditional pass-through Agency RMBS and structured Agency RMBS [4] - The company is managed by Bimini Advisors, LLC, a registered investment adviser [4] Group 5: RMBS Valuation and Characteristics - As of July 31, 2025, the total mortgage assets amounted to $7,350,578,000, with Fannie Mae and Freddie Mac representing 60.1% and 39.9% of the portfolio, respectively [11] - The company holds a significant portion of its assets in whole pool RMBS, accounting for 94.3% of total mortgage assets [12]

Company Overview - Astrotech Corporation is a mass spectrometry company that creates, operates, and scales innovative businesses through its wholly owned subsidiaries [3] - The company is headquartered in Austin, Texas [3] Subsidiaries and Their Focus - 1st Detect develops, manufactures, and markets trace detection systems for security and narcotics screening applications [4] - AgLAB designs process analyzers tailored to the agriculture industry [4] - Pro-Control produces solutions for in-situ chemical process control in industrial manufacturing [4] - BreathTech is advancing a breath analysis platform to detect volatile organic compounds (VOCs) associated with infections and critical health conditions [4] - EN-SCAN, Inc. delivers portable, ruggedized environmental testing solutions that integrate gas chromatography and mass spectrometry for use in challenging field environments [4] Investor Engagement - Thomas B. Pickens III, Chairman and CEO, and Jennifer Cañas, CFO, will host investor meetings on September 9, 2025, at the H.C. Wainwright 27th Annual Global Investment Conference in New York City [1] - Investors can register and request meetings with management via their HC Wainwright representative or Astrotech Investor Relations [2]

Core Viewpoint - Gulf Resources, Inc. reported significant improvements in financial performance for the three months ended June 30, 2025, with a notable increase in net revenue and a reduction in net loss compared to the previous year [5][10]. Financial Performance - Net revenue increased by 250% to $8,343,785 from $2,383,169 in the previous year [5]. - Gross profits rose to $986,655 from a loss of $2,728,889 [5]. - The loss from operations was $750,686 compared to a loss of $5,146,997 in the previous year [5]. - The net loss was $773,777 versus a net loss of $33,097,918 in the previous period [5]. - Loss per share improved to $0.06 from $3.09 in the previous period [5]. - Negative cash flow for the first six months of 2025 was sharply reduced from $61,856,355 to $2,339,081 [5]. Segment Performance - Bromine sales increased by 313% to $7,676,374 from $1,859,234, with volume rising by 152% to 1,972 tonnes from 782 tonnes [5]. - Crude salt revenues increased by 27% to $667,411 from $523,935, with volume increasing by 4% to 25,934 tonnes from 24,852 tonnes [5]. Market Conditions - Bromine pricing showed significant volatility, with prices fluctuating from RMB 29,000 per tonne at the end of Q1 2025 to RMB 24,686 per tonne at the end of Q2 2025, before recovering to RMB 29,200 per tonne by August 12, 2025 [2]. - The company anticipates that the price recovery and increasing overall demand may represent a sustainable market trend [2]. Operational Updates - The chemicals segment operations remain suspended pending improved market conditions, with management deferring the completion of remaining chemical factory construction [3]. - Natural gas operations are inactive while awaiting completion of provincial planning initiatives in Sichuan Province [4]. - Development activities on crude salt fields acquired in the prior year have been initiated, expected to enhance production capacity [2]. Management Outlook - The CEO expressed optimism about the business, citing signs of stabilization in the Chinese economy and increasing demand for bromine and crude salt [6]. - The company is focused on generating profits and free cash flow from bromine and crude salt segments while exploring opportunities in chemicals and natural gas [6].

Core Points - Brookfield Corporation announced a public offering of $650 million principal amount of senior notes due 2036 with an interest rate of 5.330% per annum [1][2] - The offering is expected to close on August 20, 2025, subject to customary closing conditions [1] - The net proceeds from the sale of the notes will be used for general corporate purposes [2] Company Overview - Brookfield Corporation is a leading global investment firm focused on building long-term wealth for institutions and individuals [5] - The company operates three core businesses: Alternative Asset Management, Wealth Solutions, and Operating Businesses in renewable power, infrastructure, business and industrial services, and real estate [5] - Brookfield has a track record of delivering over 15% annualized returns to shareholders for over 30 years [6]

Core Insights - Centerspace published its 2024 ESG Report and inaugural TCFD report, emphasizing its commitment to sustainable practices in the multifamily industry [1][3] - The company met four out of five ESG goals two years ahead of schedule and improved its GRESB score from 63 to 70 [2] Group 1: ESG Commitment - Centerspace's 2024 ESG report aligns with GRI's 2024 Universal Standards and the United Nations Sustainable Development Goals [2] - The company established an ESG Committee in 2019 to lead sustainability initiatives [1] Group 2: Climate Risk Management - The inaugural TCFD report serves as a foundation for managing climate risk and aligns with industry-standard reporting frameworks [3] - Centerspace is focused on continuous improvement in disclosure and climate risk mitigation [3] Group 3: Operational Practices - The company is committed to responsible business practices, including resource stewardship, waste reduction, and energy and water conservation [4] - Centerspace operates 73 apartment communities with a total of 13,773 homes across several states [4]

Core Insights - Opus Genetics has achieved significant progress in its clinical pipeline, including positive clinical data for OPGx-LCA5 and FDA's RMAT designation, indicating strong potential for vision restoration therapies [1][2][5] - The company reported positive topline results from Phase 3 trials for Phentolamine Ophthalmic Solution 0.75%, which could provide new treatment options for patients with vision challenges [1][2][13] - Financial results for Q2 2025 show an increase in collaboration revenue and a net loss reduction compared to the same period in 2024, indicating improved financial performance [9][12][22] Pipeline Updates - OPGx-LCA5, a gene therapy for Leber Congenital Amaurosis, has shown sustained visual function improvements in adult patients, with initial pediatric data indicating positive outcomes [1][5] - OPGx-BEST1 is on track to enter Phase 1/2 trials in H2 2025, targeting bestrophin-1 related inherited retinal disease [1][4][14] - Non-dilutive funding has been secured to support the advancement of multiple early-stage gene therapy programs, including OPGx-RDH12 and OPGx-MERTK [1][13] Financial Performance - As of June 30, 2025, Opus Genetics reported cash and cash equivalents of $32.4 million, expected to fund operations into the second half of 2026 [8] - License and collaboration revenue for Q2 2025 totaled $2.9 million, up from $1.1 million in Q2 2024, driven by collaboration with Viatris, Inc. [9] - General and administrative expenses increased to $5.8 million in Q2 2025 from $3.4 million in Q2 2024, primarily due to higher legal and patent-related costs [10] Upcoming Milestones - The company plans to report three-month pediatric data from the OPGx-LCA5 trial in Q3 2025 and initiate enrollment for OPGx-BEST1 in H2 2025 [14] - A supplemental New Drug Application (sNDA) for Phentolamine is expected to be submitted in the second half of 2025 [14] - Enrollment for the LYNX-3 Phase 3 trial targeting nighttime visual disturbances is anticipated to begin in H2 2025 [14]

Webcast and Conference Call Scheduled for 5:00 PM ETNEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- XWELL, Inc. (Nasdaq: XWEL) ("XWELL" or the "Company"), a leading provider of wellness solutions for people on the go, today announced that it will report second quarter 2025 financial results on Thursday, August 14, 2025, after the market close. The announcement will be followed by a webcast and conference call at 5:00 p.m. ET. The Company encourages investors, and interested parties, to listen via webcast, as th ...

Core Insights - Aptose Biosciences Inc. reported financial results for Q2 2025, highlighting progress in the TUSCANY triplet trial for treating newly diagnosed acute myeloid leukemia (AML) with tuspetinib-based therapy [1][2] Financial Performance - The net loss for Q2 2025 was $7.0 million, a decrease from $7.3 million in Q2 2024. For the first half of 2025, the net loss was $12.6 million, down from $16.9 million in the same period of 2024 [11][12] - Research and development expenses for Q2 2025 were $3.3 million, down from $4.4 million in Q2 2024. For the first half of 2025, these expenses totaled $5.7 million, compared to $10.9 million in the first half of 2024 [14][17] Clinical Development - The TUSCANY trial is advancing with promising safety and efficacy results for the tuspetinib (TUS) combination therapy, showing complete responses (CRs) across various genetic backgrounds in AML patients [4][5] - The Cohort Safety Review Committee (CSRC) recommended escalating the tuspetinib dose from 120 mg to 160 mg based on positive safety data [4][5] - Data from the TUSCANY trial was presented at the European Hematology Association (EHA) 2025 Congress, indicating that TUS can be safely combined with standard treatments [5][6] Corporate Developments - Aptose entered a loan agreement with Hanmi Pharmaceutical for up to $8.5 million to support the development of tuspetinib [6][9] - The company has been upgraded to trade on the OTCQB Market, enhancing its visibility among investors [9] - Aptose selected Ernst & Young as its new independent auditor and will hold a reconvened shareholder meeting on August 22, 2025 [9][10] Research and Development Focus - The company is focusing on the development of precision oncology therapies, particularly for hematological malignancies, with tuspetinib as a lead candidate [17][19] - Program costs for tuspetinib were $2.2 million for Q2 2025, down from $2.7 million in Q2 2024, attributed to reduced clinical trial activities [18]

Core Insights - SCYNEXIS, Inc. reported financial results for Q2 2025, highlighting progress in its drug development pipeline and ongoing disputes with GSK regarding milestone payments [1][5][9]. Drug Development Progress - The company is advancing its second-generation fungicide candidate, SCY-247, with Phase 1 Single Ascending Dose/Multiple Ascending Dose (SAD/MAD) data expected to be announced in Q3 2025 [2][7]. - Positive preclinical efficacy data for SCY-247 was presented at the ESCMID meeting, showcasing its potential against difficult-to-treat fungal infections [4]. - The first new patient was dosed in the Phase 3 MARIO study after the FDA lifted the clinical hold, triggering a $10 million milestone payment from GSK [5][6]. Financial Performance - For Q2 2025, SCYNEXIS reported revenue of $1.4 million, up from $0.7 million in Q2 2024, primarily from the GSK License Agreement [9]. - Research and development expenses increased to $7.1 million in Q2 2025 from $6.8 million in Q2 2024, driven by higher costs in chemistry, manufacturing, and controls [10]. - Selling, general, and administrative expenses rose to $3.8 million in Q2 2025, a 20% increase from $3.2 million in Q2 2024, mainly due to higher professional fees [11]. - The net loss for Q2 2025 was $6.9 million, or $(0.14) per share, compared to a net loss of $14.5 million, or $(0.30) per share in Q2 2024 [13]. Cash Position - As of June 30, 2025, the company had cash, cash equivalents, and investments totaling $46.5 million, down from $75.1 million at the end of 2024, providing a cash runway into Q4 2026 [14]. Legal Developments - The U.S. District Court granted SCYNEXIS's motion to dismiss a securities class action lawsuit filed in November 2023, allowing the plaintiff to amend the complaint within 30 days [8]. Corporate Strategy - SCYNEXIS is working to transfer the New Drug Application for Brexafemme to GSK by the end of 2025, enabling GSK to initiate regulatory discussions for the product's relaunch [6][16].

Core Insights - Planet 13 Holdings Inc. reported a revenue of $26.9 million for Q2 2025, a decrease of 13.6% compared to $31.1 million in Q2 2024, primarily due to price compression and a weaker consumer environment in Nevada, along with increased competition in Florida [5][6][8] - The company experienced a net loss of $13.3 million in Q2 2025, compared to a net loss of $8.1 million in the same quarter last year, reflecting a 64.8% increase in losses [5][6][8] - Adjusted EBITDA for Q2 2025 was a loss of $2.4 million, a significant decline from an adjusted EBITDA of $3.2 million in Q2 2024, marking a 176.1% decrease [5][6][8] Financial Highlights - Total revenue for Q2 2025 was $26.9 million, down from $31.1 million in Q2 2024, representing a 13.6% decrease [5][6][8] - Gross profit decreased to $11.7 million (43.4% margin) from $15.8 million (50.9% margin), indicating a 26.4% drop in gross profit [5][6][8] - Total expenses were reduced to $18.5 million from $19.4 million, a decrease of 4.6%, attributed to early savings from cost-cutting measures [5][6][8] Balance Sheet Overview - Cash reserves decreased to $15.9 million from $23.4 million as of December 31, 2024 [6][18] - Total assets were reported at $201.0 million, down from $206.7 million [6][18] - Total liabilities increased to $103.1 million from $94.0 million, indicating a rise in financial obligations [6][18] Operational Strategy - The company is focusing on operational discipline, tightening expenses, and implementing targeted pricing strategies to enhance its competitive position in key markets [2][3] - Planet 13 is adopting a more aggressive pricing strategy in Nevada to leverage its scale advantage, despite the challenging operating environment [2][3] Recent Developments - Planet 13 opened new dispensaries in Orange Park and Edgewater, Florida, in April 2025, expanding its footprint in key markets [12] - The company launched a revamped loyalty program in July 2025 to enhance customer engagement [12]